vida: extract claims from 2026-04-13-ww-med-plus-glp1-success-program-march-2026

- Source: inbox/queue/2026-04-13-ww-med-plus-glp1-success-program-march-2026.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/medicaid-coverage-expansion-eliminates-racial-glp1-prescribing-disparities-through-structural-access-not-provider-bias.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Natural experiment at Massachusetts tertiary care center shows Black and Hispanic patients were 47-49 percent less likely to receive GLP-1s before Medicaid coverage but disparities narrowed substantially after January 2024 policy change
+confidence: likely
+source: Wasden et al., Obesity 2026, pre-post study at large tertiary care center
+created: 2026-04-13
+title: Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias
+agent: vida
+scope: causal
+sourcer: Wasden et al., Obesity journal
+related_claims: ["[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
+---
+
+# Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias
+
+Before Massachusetts Medicaid (MassHealth) expanded GLP-1 coverage for obesity in January 2024, Black patients were 49% less likely and Hispanic patients were 47% less likely to be prescribed semaglutide or tirzepatide compared to White patients (adjusted odds ratios). After the coverage expansion, these disparities 'narrowed substantially' according to the authors. This natural experiment design provides stronger causal evidence than cross-sectional studies because it isolates the policy change as the intervention. The magnitude of the pre-coverage disparity (nearly 50% reduction in likelihood) and its substantial narrowing post-coverage demonstrates that structural barriers—specifically insurance coverage—are the primary driver of racial disparities in GLP-1 prescribing, not implicit provider bias alone. The study was conducted at a single large tertiary care center, so generalizability requires replication, but the pre-post design within the same institution controls for provider composition and practice patterns. Separate tirzepatide prescribing data showed adjusted odds ratios vs. White patients of 0.6 for American Indian/Alaska Native, 0.3 for Asian, 0.7 for Black, 0.4 for Hispanic, and 0.4 for Native Hawaiian/Pacific Islander patients, confirming the disparity pattern across multiple racial/ethnic groups.

domains/health/uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Despite substantial clinical evidence supporting an A/B rating for GLP-1 pharmacotherapy, no formal petition has been filed and no update process is publicly announced, leaving the most powerful single policy lever for mandating coverage unused
+confidence: proven
+source: USPSTF 2018 Adult Obesity Recommendation, verified April 2026 status check
+created: 2026-04-13
+title: The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes
+agent: vida
+scope: structural
+sourcer: USPSTF
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]"]
+---
+
+# The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes
+
+The USPSTF's 2018 Grade B recommendation for adult obesity covers only intensive multicomponent behavioral interventions (≥12 sessions in year 1). While the 2018 review examined pharmacotherapy, it covered only orlistat, lower-dose liraglutide, phentermine-topiramate, naltrexone-bupropion, and lorcaserin—therapeutic-dose GLP-1 agonists (Wegovy/semaglutide 2.4mg, Zepbound/tirzepatide) were entirely absent from the evidence base as they did not exist at scale. The recommendation explicitly declined to recommend pharmacotherapy due to 'data lacking about maintenance of improvement after discontinuation.' As of April 2026, this 2018 recommendation remains operative. The USPSTF website flags adult obesity as 'being updated' but the redirect points toward cardiovascular prevention (diet/physical activity), not GLP-1 pharmacotherapy. No formal petition or nomination for GLP-1 pharmacotherapy review has been publicly announced. This matters because a new USPSTF A/B recommendation covering GLP-1 pharmacotherapy would trigger ACA Section 2713 mandatory coverage without cost-sharing for all non-grandfathered insurance plans—the most powerful single policy lever available, more comprehensive than any Medicaid state-by-state expansion. The clinical evidence base that could support an A/B rating (STEP trials, SURMOUNT trials, SELECT cardiovascular outcomes data) exists and is substantial. Yet the policy infrastructure has not caught up to the clinical evidence, and no advocacy organization has apparently filed a formal nomination to initiate the review process. This represents a striking policy gap: the most powerful available mechanism for mandating GLP-1 coverage sits unused despite strong supporting evidence.

domains/health/wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Access timing inversion shows structural inequality operates not just through yes/no access but through when-in-disease-course treatment begins with 13 percent higher BMI at initiation for poorest patients
+confidence: likely
+source: Wasden et al., Obesity 2026, wealth-stratified treatment initiation analysis
+created: 2026-04-13
+title: Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients
+agent: vida
+scope: structural
+sourcer: Wasden et al., Obesity journal
+related_claims: ["[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"]
+---
+
+# Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients
+
+Among Black patients receiving GLP-1 therapy, those with net worth above $1 million had a median BMI of 35.0 at treatment initiation, while those with net worth below $10,000 had a median BMI of 39.4—a 13% higher BMI representing substantially more advanced disease progression. This reveals that structural inequality in healthcare access operates not just as a binary (access vs. no access) but as a temporal gradient where lower-income patients receive treatment further into disease progression. The 4.4-point BMI difference represents years of additional disease burden, higher comorbidity risk, and potentially reduced treatment efficacy. This finding demonstrates that even when access is eventually achieved, the timing disparity creates differential health outcomes based on wealth. The pattern suggests that higher-income patients access GLP-1s earlier in the obesity disease course, potentially through cash-pay or better insurance, while lower-income patients must wait until disease severity is higher before qualifying for or affording treatment.

entities/health/uspstf.md

@@ -0,0 +1,15 @@
+# United States Preventive Services Task Force (USPSTF)
+
+## Overview
+Independent panel of national experts in prevention and evidence-based medicine that makes recommendations about clinical preventive services. USPSTF A/B recommendations trigger ACA Section 2713 mandatory coverage without cost-sharing for all non-grandfathered insurance plans.
+
+## Key Mechanism
+USPSTF recommendations are the most powerful single policy lever for mandating coverage of preventive services in the US healthcare system. Grade A/B recommendations automatically trigger mandatory coverage requirements under the Affordable Care Act.
+
+## Timeline
+- **2018-09-18** — Published Grade B recommendation for adult obesity covering intensive multicomponent behavioral interventions (≥12 sessions in year 1); reviewed pharmacotherapy but declined to recommend due to insufficient maintenance data; therapeutic-dose GLP-1 agonists not yet available
+- **2024** — Updated children and adolescents obesity recommendation (behavioral-only, did not address adult pharmacotherapy)
+- **2026-04** — Adult obesity topic flagged as 'being updated' on website but redirect points toward cardiovascular prevention rather than GLP-1 pharmacotherapy; no formal petition for GLP-1 review publicly announced
+
+## Policy Gap
+As of April 2026, the 2018 recommendation remains operative despite substantial clinical evidence base for therapeutic-dose GLP-1 agonists (STEP trials, SURMOUNT trials, SELECT cardiovascular outcomes data) that could support an A/B rating. No formal nomination or petition process for GLP-1 pharmacotherapy review has been initiated.

inbox/archive/health/2026-04-13-ww-med-plus-glp1-success-program-march-2026.md

@@ -7,9 +7,12 @@ date: 2026-03-01
 domain: health
 secondary_domains: []
 format: report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-13
 priority: medium
 tags: [glp1, behavioral-wraparound, adherence, weight-loss, digital-health, ww-med-plus]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content